ClinicalTrials.gg
RecruitingNCT06604520Updated Mar 9, 2026

Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia

A Phase 2 interventional study of Vortioxetine in Fronto-temporal Dementia, Fronto-temporal Lobar Dementia and Frontotemporal Degeneration, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Johns Hopkins University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.

Planned enrollment
36th of 66
50 · median 60
Started
2025
with 5 others
Phase 2
14 of 103
4 open now
Primary completion
2029-05
later than 29 of 44 live
Registered
93rd of 103
by date
Lead sponsor
4 of 103
Johns Hopkins University

Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 36th largest by planned enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2025, is one of 14 in phase 2, reaches primary completion later than 29 of the 44 other live ones, and was the 93rd registered.

Frontotemporal Dementia

208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.

Browse Frontotemporal Dementia studies →

Open to participants now

31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.

This study: 45 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Frontotemporal Dementia with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions this study aims to answer are:

  1. Do individuals with mood symptoms and bvFTD have brain changes and cognitive profiles that differ compared to individuals without bvFTD?
  2. Do mood symptoms and cognition improve following treatment with vortioxetine?

Researchers will also determine whether there are changes in the brain associated with vortioxetine treatment.

Participants will:

  • Undergo a screening visit that involves clinical assessments and laboratory tests
  • Undergo an initial brain magnetic resonance imaging (MRI) and fluorodeoxyglucose (18F) Positron Emission Tomography (FDG PET) scan before starting treatment with vortioxetine
  • Undergo memory and problem-solving tests before starting treatment with vortioxetine
  • Undergo approximately 12 weeks of treatment with vortioxetine, during which time there will be regular contact and assessments with the study psychiatrist
  • Undergo a repeat PET scan and repeat memory and problem-solving tests after 12 weeks of treatment with vortioxetine
03

Conditions studied

  • Fronto-temporal Dementia
  • Fronto-temporal Lobar Dementia
  • Frontotemporal Degeneration
  • Frontotemporal Dementia (FTD)
  • Frontotemporal Dementia, Behavioral Variant
  • Frontotemporal Dementia

Keywords

  • FTD
  • Frontotemporal Dementia
  • Neuropsychiatric Symptoms
  • Antidepressant
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

FTD Patients

Inclusion Criteria:

  1. Male or Female
  2. Age 45 and above
  3. Diagnosis of possible or probable bvFTD based on international consensus criteria for behavioral variant FTD (FTDC)
  4. The presence of at least one of the following affective symptoms on the 12-item Neuropsychiatric Inventory: depression, anxiety, irritability, or agitation
  5. A global Clinical Dementia Rating (CDR®) plus National Alzheimer's Coordinating Center (NACC) Frontotemporal lobar degeneration (FTLD) Behavior and Language Domains global score (CDR® plus NACC FTLD) less than or equal to one
  6. Patients must be medically stable
  7. Vortioxetine treatment is clinically indicated
  8. Competent to provide

Exclusion Criteria:

  1. No history of drug or alcohol dependence within six months prior to study entry
  2. Negative toxicology screening for drugs of abuse
  3. Subject must not be pregnant or nursing
  4. No to Vortioxetine treatment
  5. No contraindications for Magnetic Resonance (MR) scanning (e.g. metal implanted in the body)

Healthy Controls

Inclusion Criteria:

  1. Male or Female
  2. Age 45 and above
  3. Subjects must be medically stable
  4. Free of psychotropic medications
  5. Competent to provide informed consent

Exclusion Criteria:

  1. No current or past history of neurological or psychiatric illness or substance abuse
  2. Subject must not be pregnant or nursing
  3. Negative toxicology screening for drugs of abuse
  4. No contraindications for MR scanning (e.g. metal implanted in the body)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Patient Treatment Arm (Vortioxetine)

    Individuals with bvFTD and mood symptoms receiving the study drug, vortioxetine.

    Drug: Vortioxetine

Interventions

  • Individuals with bvFTD and mood symptoms will receive approximately 12 weeks of treatment with vortioxetine

    Also known as: Trintellix

06

What researchers measure

Primary outcomes

  1. Change in global cerebral glucose metabolism on [18F] fluorodeoxyglucose Positron Emission Tomography (FDG PET)

    Cerebral glucose uptake measured through 18F FDG positron emission tomography

    Time frame: Baseline, 12 weeks

Secondary outcomes

  1. Change in depressive symptoms as assessed by the Hamilton Depression Rating Scale (HDRS).

    The HDRS is a widely used clinician-administered depression assessment tool designed to measure the severity of depression in individuals. It consists of 17 items rated on a 3 or 5 point scale with total scores ranging from 0 to 52. A higher score indicates more severe symptoms of depression.

    Time frame: Baseline, 12 weeks

Other outcomes

  1. Change in performance on the Trail Making Test (TST).

    The TMT is a widely used neuropsychological test that assesses an individuals cognitive abilities including executive function, attention, processing speed, and mental flexibility. It is divided into two parts: Trail Making Test A and Trail Making Test B. The Trail Making Test A primarily assesses visual attention and processing speed. Time taken to complete the task is recorded, with faster times indicating better cognitive performance. The Trail Making Test B primarily assesses cognitive flexibility, executive functioning, task switching and attention. Time taken to complete the task is recorded, with faster times indicating better cognitive performance.

    Time frame: Baseline, 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All de-identified data will be preserved and shared in the National Archive of Computerized Data on Aging (NACDA).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will shared 12 months after study starts and every 6 months thereafter. All data will be shared upon publication or at the end of the award period, whichever is sooner. For published studies, data will be shared when the pre- print is available. NACDA studies have digital object identifiers (DOI) to aid in findability. The investigators will include that DOI in relevant publications. NACDA will make decisions about how long to preserve the data, but that data archive has not deleted any deposited data up to now.

Access criteria: Given that all data will be de-identified, the investigators do not plan to control access to the data or require a Data Use Agreement. Data submitted to NACDA that are evaluated as constituting a low disclosure risk are publicly released and available to download directly from the NACDA website. The investigators plan to prepare and submit the data in a de-identified format in order to minimize any disclosure risk and allow for public release through NACDA. NACDA performs an evaluation of all submitted data prior to release to ensure disclosure risks are minimized, and the investigators anticipate approval for public release of data without restriction through the NACDA website.

Data sharing details ↗ · www.icpsr.umich.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for May 2029, 50 months after the start.

Of 19 phase 2 interventional studies under Frontotemporal Dementia, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 64. This study's planned 50 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Sep 19, 2024
StartActual
Mar 20, 2025
Primary completionEst.
May 31, 2029
CompletionEst.
Sep 1, 2029
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06604520
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Mar 20, 2025
Primary completion
May 31, 2029 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Mar 9, 2026

Study contacts

Christopher B Morrow, MD
Contact
cmorrow3@jhmi.edu
410-502-6509
Christopher Morrow, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion